Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes
Michel Vierboom(Biomedical Primate Research Centre), Cornelis J.M. Melief(ISA Pharmaceuticals (Netherlands)), W. Martin Kast(University of Southern California), Peter Kenemans, Hans W. Nijman(University Medical Center Groningen), Thorbald van Hall(Leiden University Medical Center), Lambert van den Broek(Leiden University), Rienk Offringa(German Cancer Research Center), Ellen I. H. van der Voort(Leiden University), Gert Jan Fleuren(Leiden University Medical Center)
Cited by 211
Related Papers
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
|British Journal of Cancer|2011|1.3k
Therapeutic cancer vaccines
|Journal of Clinical Investigation|2015|1.1k
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
Tumor-infiltrating lymphocytes in the immunotherapy era
|Cellular and Molecular Immunology|2020|919